Abstract | PURPOSE: METHODS: RESULTS: Optic nerve ligation led to a transient increase in uPA and plasmin proteolytic activity in the retina. Urokinase inhibitor, amiloride, blocked uPA activity in retinal extracts. We found a correlation between the increased uPA activity, and conversion of zymogen plasminogen to active plasmin in retinal extracts with laminin degradation in the retina and apoptosis of ganglion cells. We found that by adding exogenous plasmin, in vitro, laminin present in control retinal extracts could be degraded in similar fashion. In addition, uPA or tPA failed to degrade laminin in control retinal extracts unless plasminogen was added, indicating that plasminogen activation is necessary for laminin degradation, in vitro. After intravitreal injection of plasmin inhibitor, alpha-2 antiplasmin, we found a significant protection against optic nerve ligation-induced ganglion cell loss. CONCLUSIONS:
|
Authors | Xu Zhang, Aisha Chaudhry, Shravan K Chintala |
Journal | Molecular vision
(Mol Vis)
Vol. 9
Pg. 238-48
(Jun 12 2003)
ISSN: 1090-0535 [Electronic] United States |
PMID | 12813409
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Laminin
- Plasminogen Inactivators
- Serine Proteinase Inhibitors
- alpha-2-Antiplasmin
- Amiloride
- Plasminogen
- Plasminogen Activators
- Tissue Plasminogen Activator
- Fibrinolysin
- Urokinase-Type Plasminogen Activator
|
Topics |
- Amiloride
(pharmacology)
- Animals
- Apoptosis
- Blotting, Western
- Cell Survival
(physiology)
- Cytoprotection
- Fibrinolysin
(antagonists & inhibitors, metabolism)
- Immunoenzyme Techniques
- In Situ Nick-End Labeling
- Laminin
(metabolism)
- Ligation
- Mice
- Optic Nerve
- Plasminogen
(antagonists & inhibitors, metabolism)
- Plasminogen Activators
(antagonists & inhibitors, metabolism)
- Plasminogen Inactivators
(pharmacology)
- Reperfusion Injury
(metabolism, pathology, prevention & control)
- Retinal Diseases
(metabolism, pathology, prevention & control)
- Retinal Ganglion Cells
(cytology, metabolism)
- Serine Proteinase Inhibitors
(pharmacology)
- Tissue Plasminogen Activator
(antagonists & inhibitors, metabolism)
- Urokinase-Type Plasminogen Activator
(antagonists & inhibitors, metabolism)
- alpha-2-Antiplasmin
(pharmacology)
|